The European Brain Council (EBC) is very pleased to announce the launch of updated disease fact sheets, providing a quick overview of key facts, history, known causes, diagnosis, symptoms and treatment of brain disorders – neurological and mental alike.
The European Brain Research Area project – EBRA – was created as a catalyzing platform for brain research stakeholders (researchers, clinicians, patients, governments, funders and public institutions) to streamline and better coordinate brain research across Europe.
RETHINKING MS in Europe,
offering tangible policy changes to improve the lives of people living with MS
across Europe, went live during Brain Awareness Week
the occasion of the Brain Awareness Week (16-22 March 2020), the
European Brain Council… Continue Reading
Meeting of WHO with EFNA, EAN and EBC to discuss brain health Report
Platform for all participants to present their ongoing work and discuss potential collaboration in the area of brain health
European Academy of Neurology (EAN): Raad… Continue Reading
The AD Detect and Prevent project, which is funded through Horizon 2020 and led by the Danish digital therapeutics company Brain+, aims to develop a robust digital tool for improving the early detection of Alzheimer’s disease (AD). This integrated tool aims to first detect subtle cognitive signs associated with Alzheimer’s disease (before the possible emergence of clear symptoms) and to subsequently provide personalized intervention programmes that address risk factors connected to Alzheimer’s dementia.
Science|Business is canvassing views on the big research priorities for the next term of the EU, from 2019 to 2024. Here, six policy experts discuss the most pressing items on the EU’s to-do list for health.
In the continuity of the Value of Treatment research activities, new case studies have been developed on new therapeutic areas. On March 26th, May 23rd and September 24th 2018, EBC in collaboration with the European Academy of Neurology (EAN) and the European Federation of Neurological Associations (EFNA) launched a second round “VoT2” of case studies on Rare Neurological Disorders (RNDs) focusing upon Ataxia, Dystonia and Phenylketonuria